

6. Reference

1. A Situational Analysis of Human Resource Issues in the Pharmacy Profession in (ASAHR) Canada Human Resources Development Canada, 2001 Accessed 15 July 2011.
2. Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. *Best Pract Res Clin Gastroenterol.* 2007.
3. Alkatheri, A and A Albekairy. Does the patients' educational level and previous counseling affect their medication knowledge. *Annals of Thoracic Medicine,* 2013; 8:105-108.
4. Allegaert K, van Mieghem T, Verbesselt R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. *Am J Obstet gynecol.*2009
5. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. *Clin Pharmacokinet.* 2005;44(10):989–1008
6. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. *Am J Obstet Gynaecol.* 2004;191:398–407
7. Bogen DL, Perel JM, Helsel JC, et al. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment *psychopharmacology.*2013; 225(2);441-451
8. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. *Am J Hosp Pharm.* 1991
9. Bramankar DM, Sunil B, Jaiswal, *Biopharmaceutics and Pharmacokinetics textbook. A treatise,* (2009)
10. Braun L, Cohen M. *Herbs and Natural Supplements.* 3 ed; 2010
11. Briggs GG. Drug effects on the fetus and breastfed infants. *Clin Obstet Gynaecol.* 2002;45:6–21
12. Broussard CS, Louik C, Honein MA, et al. Herbal use before and during pregnancy. *Am J Obstet Gynecol.* 2010;202(5):443.e1–443. e6. 48.
13. CDC 2016 .Pregnant Women & Influenza (Flu,).
14. Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. *Am J Obstet Gynecol.* 1993;168(2):667–673
15. Cipolle RJ, Strand LM, Morley PC. *Pharmaceutical care practice.* New York: McGraw-Hill, 1998
16. Cruthirds DL, Hughes PJ, Weaver S. Value of pharmacy services to the healthcare system: an interdisciplinary assessment. *International J Pharm Pract,* 2013; 21(1):38-45

17. Damase-Michel C, C. Vié, I. Lacroix, M. Lapeyre-Mestre, J.L. Montastruc Drug counselling in pregnancy: an opinion survey of French community pharmacists
18. Dante G, Pedrielli G, Annessi E, et al. Herb remedies during pregnancy: a systematic review of controlled clinical trials. *J Matern Fetal Neonatal Med.*
19. Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. *Kidney Int.* 1980;18(2):152–161
20. De Jong LT, Van den Berg PB. A study of drug utilization during pregnancy in the light of known risks. *Int J Risk Safety Med.* 1990;1:91–105
21. Ezeudo EN, Jegbefume MO, Cletus NA. Pharmaceutical care interventions, their outcomes and patients' satisfaction in antiretroviral drug therapy. *Int J Dev Sustain* 2013;2:430–44
22. Felkey BG. Adherence screening and monitoring. *Am Pharm.* 1995; NS35(Jul):42–51.
23. Food Safety Authority Ireland (FSAI) 2011 Best Practice for infant feeding in Ireland. Dublin. FSAI 2011 Scientific Recommendations for a National Infant Feeding Policy, 2nd Edition. Dublin.
24. Foster SL, Smith EB, Seybold MR. Advanced counseling techniques: integrating assessment and intervention. *Am Pharm.* 1995;
25. Go, AS; Bauman, M; King, SM; Fonarow, GC; Lawrence, W; Williams, KA; Sanchez, E (Nov 15, 2013). "An Effective Approach to High Blood Pressure Control: A Science Advisory From the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention". *Hypertension.* 63 (4): 878–85
26. Gordon MV, McMahon LP, Hamblin PS. Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy. *Med J Aust.* 2005;182(7):350–1.
27. Ginsberg HN and Goldberg IJ (2001). Disorders of protein metabolism. In: Braunwald, Fauci Kasper et al 'editors'. *Harrison's Principles of Internal Medicine.* United States of America: McGraw-Hill publishers, New York, 15th ed., pp.2245-2256
28. Grincevičienė, Š L. Kubilienė, K. Ivanauskas, G. Drąsutienė, D Experiences of community pharmacists advising pregnant women.
29. Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. *Ann Epidemiol.* 2005;15(6):460–466

30. Guay J, Grenier Y, Varin F: Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. *Clin Pharmacokinet* 34: 483, 1998
31. Haag S, Andrews JM, Katelaris PH, Gapasin J, Galmiche JP, Hunt R, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. *Digestion*. 2009;80(4):226–234.
32. Haas DM, Quinney SK, Clay JM, et al. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. *Am J Perinatol*. 2013;30(4):275–281
33. Hagstedt S, Rane A: Plasma concentration-effect relationship of metoprolol during and after pregnancy. *Eur J Clin Pharmacol* 44: 243, 1993
34. Hämeen-Anttila K., J. Jyrkkä, H. Enlund, H. Nordeng, A. Lupattelli, E. Kokki Medicines information needs during pregnancy: a multinational comparison
35. Hansen W, Yankowitz J. Pharmacologic therapy for medical disorders during pregnancy. *Clin Obstet Gynaecol*. 2002;45:136–52
36. Harden R.M, L.M. Laidlaw, *Essential Skills for a Medical Teacher. An Introduction to Teaching and Learning in Medicine* 2012.
37. Hatoum HT, Hutchinson RA, Lambert BL. OBRA 90: patient counseling—enhancing patient outcomes. *US Pharm*. 1993; 18(Jan):76–86
38. Hawkins DW, Fiedler FP, Douglas HL and Eschbach RC (1979). Evaluation of a clinical Pharmacist in caring for hypertensive and diabetic patients. *Am. J. Hosp. Pharm.*, 36: 1321-1325
39. Hayashi M, Ueda Y, Hoshimoto K, et al. Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia. *Am J Kidney Dis*. 2002;39(2):392–400
40. Hebert MF, Carr DB, Anderson GD, et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. *J Clin Pharmacol*. 2005;45(1):25–33
41. Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. *Clin Pharmacol Ther*. 2008;84(2):248–253
42. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Pharm Ed* 1989;53

43. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. *Am J Hosp Pharm.* 1990.
44. Herrier RN, Boyce RW. Does counseling improve compliance? *Am Pharm.* 1995; NS35(Sep):11–2
45. HSE 2010 Guidelines for the management of pre-gestational diabetes Mellitus from preconception to the postnatal period July 2010 available at www.hse.ie
46. Hughes G. Friendly pharmacokinetics: a simple introduction. *Nurse Prescribing* 14(1):34-43, 2016
47. Hussain A, Ibrahim MI, Baber ZU. Using the potentials of community pharmacies to promote rational drug use in Pakistan: An opportunity exists or lost? *J Pak Med Assoc.*, 2012; 62:1217-1222.
48. International Pharmaceutical Federation (FIP), 2013. FIP reference paper on the effective utilization of pharmacists in improving maternal, newborn and child health (MNCH)
49. Jaber LA, Halapy H, Fernet M, Tummalapalli S and Dewakran H (1996). Evaluation of pharmaceutical care model on diabetes management *The Annals of Pharmacotherapy*, 30: 238-2.
50. Jusko WJ, Ko HC, Ebling WF: Convergence of direct and indirect pharmacodynamic response models. *J Pharmacokinet Biopharm* 23: 5, 1995
51. Kathy Lococo, RT. 2010. Pharmacists' Roles and Responsibilities in Counseling Patients Regarding Medications and Driving Risk. *Pharmacists' duty to warn*
52. Khan TM, MA Hassali and MSM Al-Haddad. Patient-physician Communication Barrier: A Pilot Study Evaluating Patient Experiences. *J Young Pharm*, 2011; 3:250-255
53. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* 2013;108(3):308–328
54. Kolasa, KM and K Rickett. Barriers to providing nutrition counseling cited by physicians: a survey of primary care practitioners. *Nutr Clin Pract*, 2010; 25:502-509
55. Kennedy D.A., A. Lupattelli, G. Koren, H. Nordeng, Herbal medicine use in pregnancy: results of a multinational study (2015)
56. Lee YJ, Kusuvara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. *J Pharmacol Exp Ther.* 2005;312(1):44–52

57. Lenz TL and Stading JA Lifestyle Modification Counseling of Patient with Dyslipidemia by Pharmacists and Other Health Professions. 2005; 45(6):709-1 and Stading JA. Lifestyle Modification Counseling of Patient with Dyslipidemia by Pharmacists and Other Health Professions 2005; 45(6):709-1.
58. Lupattelli, O. Spigset, M.J. Twigg, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study
59. Lyszkiewicz, G. Koren, A. Einarson, S. Gerichhausen, I. Björnsdóttir, T. Einarson, Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries
60. LZ B. Pharmacokinetics: absorption, distribution, and elimination. In: BG K, editor. Basic and Clinical Pharmacology. Appleton & Lange: East Norwalk: Conn; 1992.
61. Mahadevan U, Kane S. American Gastroenterological Association Institute medical position statement on the use of gastrointestinal medications in pregnancy Gastroenterology. 2006;131(1).
62. Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):849–77.
63. Mason CW, Buhimschi IA, Buhimschi CS, Dong Y, Weiner CP, Swaan PW. ATP-binding cassette transporter expression in human placenta as a function of pregnancy condition. Drug Metab Dispos. 2011;39(6):1000–1007
64. Medication use in an imperfect world: drug misadventuring as an issue of public Manasse HR Jr policy, part 2. Am J Hosp Pharm. 1989;
65. Mehos BM, Saseen JJ and Mac Laughlin EJ (2000). Effect of pharmacist and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy, 20: 1384-1389.
66. Ministry of Health, Republic of Serbia (MHRS), 2005, Health care of women during pregnancy. National guideline for physicians in primary health care
67. Nanavati MS. Obstetrics Handbook for Maternal Health. 1st ed. Mumbai: Niche Laboratories Ltd; 1994.
68. National Institute for Health and Clinical Excellence (NICE) (2008) (B) Maternal and Child Nutrition.

69. Nava-Ocampo AA, Valázquez-Armenta EY, Han JY, Koren G. Use of proton pump inhibitors during pregnancy and breastfeeding. *Can Fam Physician*. 2006;52:853–4.
70. Ngoh, LN. Health literacy: A barrier to pharmacist–patient communication and medication adherence. *Journal of the American Pharmacists Association*, 2009; 49: e132-e149.
71. Norwegian Directorate of Health (NDH), 2005, National professional guideline for antenatal care.
72. O'Donnell Dannielle C., CMB, Homa B. Dastani. Barriers to Counseling Patients With Obesity: A Study of Texas Community Pharmacists. *J Am Pharm Assoc*, 2006; 64:465-471
73. Pangle BL. Drugs in Pregnancy and Lactation. In: Herfindal ET, Gourley DR, editors. Text book of Therapeutics, Drug and Disease Management. 8th ed. Philadelphia: Lippincott William Wilkins; 2006. pp. 434–48.
74. Porter RS, editor. The Merck Manual's Online Medical Library. Whitehouse Station: Merck Research Lab; 2004.
75. Quinlan, 2015 J.D Nausea and vomiting in pregnancy,
76. Qasqas SA, McPherson C, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactations, *Cardiol Rev*. 2004; 12 (4); 201-221
77. Raehl CL, Bond CA, Woods TJ, Patry RA, Sleeper RB. Screening tests for intended medication adherence among the elderly. *Annals of Pharmacotherapy* 2006; 40:888-893.
78. Rantucci, MJ. 2007. *Pharmacists Talking With Patients: A Guide to Patient Counseling*, Williams & Wilkins
79. Richter JE. Review article: the management of heartburn in pregnancy. *Aliment Pharmacol Ther*. 2005;22(9):749–57.
80. Sanii Y ,Torkamandi H, Gholami K, Hadavand N, Javadi M. Role of pharmacist counseling in pregnancy women.
81. Schrempp S, A. Ryan-Haddad, K.A. *Gait Pharmacist counselling of pregnant or lactating women*.
82. Schubert ML. Gastric secretion. *Curr Opin Gastroenterol*. 2010;26(6):598–603.
83. Shareef J, Fernandes J, Samaga L, Bhat ML (2016) Evaluating the Effect of Pharmacist's Delivered Counseling on Medication Adherence and Glycemic Control in Patients with Diabetes Mellitus. *J Diabetes Metab* 7:654. .

84. Sharma R, Kapoor B, Verma U. Drug utilization pattern during pregnancy in North India. *J Med Sci.* 2006;60:277–87
85. Smiley RM, Finster M. Do receptors get pregnant too? Adrenergic receptor alterations in human pregnancy. *J Maternal Fetal Med* 5:106, 1996
86. Sorensan MK, Phillips BB, Mutnick AH. Drug use in specific patient populations: Pediatric, Pregnant, Geriatric. In: Shargel L, Mutnick A, editors. *Comprehensive Pharmacy Review*. 5th ed. Philadelphia: Lippincott William Wilkins; 2004. pp. 673–82
87. Subish Palaian, MPaPRS. Patient counseling by pharmacist - A focus on chronic illness. *Pak. J. Pharm. Sci.* 2006; 19:62-65.
88. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. *Clin Pharmacokinet.* 2004;43(8):487–514
89. Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. The impact of pharmacist face-to-face counseling to improve medication adherence among patients initiating statin therapy. *Patient Prefer Adherence*, 2012; 6:323-329.
90. Tsutsumi K, Kotegawa T, Matsuki S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. *Clin Pharmacol Ther.* 2001;70(2):121–125.
91. U.S. Food and Drug Administration Food Safety for Moms-to-Be: before you're pregnant—folic acid. (2014).
92. Waldum HL, Straume BK, Lundgren R. Serum group I pepsinogens during pregnancy. *Scand J Gastroenterol.* 1980;15(1):61–63.
93. WHO Consultative Group. 1997. *The Role of the Pharmacist in the Health-Care System - Preparing the Future Pharmacist: Curricular Development*. Vancouver, Canada.
94. Wilbur K, SES, E. Mohammadi. Patient perceptions of pharmacist roles in guiding self-medication of over-the-counter therapy in Qatar. *Patient Preference and Adherence*, 2010; 4:87-93.
95. Wong CA, McCarthy RJ, Fitzgerald PC, Raikoff K, Avram MJ. Gastric emptying of water in obese pregnant women at term. *Anesth Analg.* 2007;105:751–5.
96. Wyska EB, Jusko WC: Approaches to pharmacokinetic and pharmacodynamic modeling during pregnancy. *Semin Perinatol* 25: 124, 2001.

97. Yankowitz J, Niebyl JR, editors. Drug therapy in pregnancy. 3rd ed. Philadelphia: Lippincott William Wilkins; 2001.
98. Yeboah D, Sun M, Kingdom J, et al. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. *Can J Physiol Pharmacol.* 2006;84(12):1251–1258.